These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24632069)

  • 21. The effect of MAPK inhibitors on arsenic trioxide-treated Calu-6 lung cells in relation to cell death, ROS and GSH levels.
    Han YH; Moon HJ; You BR; Kim SZ; Kim SH; Park WH
    Anticancer Res; 2009 Oct; 29(10):3837-44. PubMed ID: 19846917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apoptosis in arsenic trioxide-treated Calu-6 lung cells is correlated with the depletion of GSH levels rather than the changes of ROS levels.
    Han YH; Kim SH; Kim SZ; Park WH
    J Cell Biochem; 2008 Jun; 104(3):862-78. PubMed ID: 18393359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MAPK inhibitors and siRNAs differentially affect cell death and ROS levels in arsenic trioxide-treated human pulmonary fibroblast cells.
    Park WH
    Oncol Rep; 2012 May; 27(5):1611-8. PubMed ID: 22293863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains.
    Zhao S; Zhang X; Zhang J; Zhang J; Zou H; Liu Y; Dong X; Sun X
    J Chemother; 2008 Apr; 20(2):253-62. PubMed ID: 18467254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of arsenic trioxide-induced apoptosis by 8-bromo-7-methoxychrysin in human leukemia cells involves depletion of intracellular reduced glutathione.
    Xiao G; Tang X; Yao C; Wang C
    Acta Biochim Biophys Sin (Shanghai); 2011 Sep; 43(9):712-21. PubMed ID: 21785114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of arsenic trioxide on cell death, reactive oxygen species and glutathione levels in different cell types.
    Han YH; Moon HJ; You BR; Kim SZ; Kim SH; Park WH
    Int J Mol Med; 2010 Jan; 25(1):121-8. PubMed ID: 19956910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
    Jiang H; Ma Y; Chen X; Pan S; Sun B; Krissansen GW; Sun X
    Cancer Sci; 2010 Apr; 101(4):975-83. PubMed ID: 20219070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of cytotoxicity induced by arsenic trioxide (a potent anti-APL drug) in rat cardiac myocytes.
    Raghu KG; Cherian OL
    J Trace Elem Med Biol; 2009; 23(1):61-8. PubMed ID: 19203718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
    Yan H; Wang YC; Li D; Wang Y; Liu W; Wu YL; Chen GQ
    Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH.
    Han YH; Kim SZ; Kim SH; Park WH
    Cancer Lett; 2008 Oct; 270(1):40-55. PubMed ID: 18539383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro exposure to quercetin and genistein alters lipid peroxides and prevents the loss of glutathione in human progenitor mononuclear (U937) cells.
    Boadi WY; Iyere PA; Adunyah SE
    J Appl Toxicol; 2005; 25(1):82-8. PubMed ID: 15669027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo.
    Wick W; Stock J; Seyfried J; Baumgart J; Wüllner U; Weller M
    Int J Oncol; 2002 Jul; 21(1):213-20. PubMed ID: 12063571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2.
    Reber U; Wüllner U; Trepel M; Baumgart J; Seyfried J; Klockgether T; Dichgans J; Weller M
    Biochem Pharmacol; 1998 Feb; 55(3):349-59. PubMed ID: 9484802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
    Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
    Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
    Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
    Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
    Yang B; Keshelava N; Anderson CP; Reynolds CP
    Cancer Res; 2003 Apr; 63(7):1520-6. PubMed ID: 12670899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
    Liu ZM; Tseng JT; Hong DY; Huang HS
    Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):493-8. PubMed ID: 16563655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
    Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.
    Biswas S; Zhao X; Mone AP; Mo X; Vargo M; Jarjoura D; Byrd JC; Muthusamy N
    Leuk Res; 2010 Jul; 34(7):925-31. PubMed ID: 20171736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.